Borislava G. Pavlova

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

Hartmut J. Ehrlich, Markus Müller, Helen May‐Lin Oh et al. · New England Journal of Medicine · 2008 · 274 citations · Full text

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Joan Cox Gill, Giancarlo Castaman, Jerzy Windyga et al. · Blood · 2015 · 153 citations · Full text

Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency

Joseph A. Church, Heinz Leibl, Mark R. Stein et al. · Journal of Clinical Immunology · 2006 · 78 citations

Primary Immunodeficiency, New 10, Autoimmune Disease +10

Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN®: Results of two large phase 3 clinical studies

Alexandra Loew-Baselli, Ryszard Konior, Borislava G. Pavlova et al. · Vaccine · 2006 · 74 citations

Vaccination, Vaccine Safety, Vaccine Development +9

Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN^®0.5 ml in adults aged 18-67 years

Alexandra Loew-Baselli, Eva-Maria Poellabauer, Borislava G. Pavlova et al. · Human Vaccines · 2009 · 59 citations · Full text